June 2012. Volume 8. Number 2

Is it efficient to universal neonatal screening for congenital adrenal hyperplasia 21-hydroxylase deficiency?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y et al; DHCSF Study Group. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med. 2012;166:113-20.
Reviewers: Fernández Rodríguez M1, Orejón de Luna G2.
1Centro de Salud de Potes. Madrid. España.
2CS General Ricardos. Madrid. España.
Correspondence: Mercedes Fernández Rodríguez. Email: mer763@hotmail.com
Reception date: 29/04/2012
Acceptance date: 17/05/2012
Publication date: 23/05/2012

Abstract

Authors' conclusions: efficiencyof screening for congenital adrenal hyperplasia 21-hydroxylase deficiency was moderate in term infants and very low inpreterm infants. The authors recommend the discontinuation of screening as has been done so far, in premature infants.

Reviewers' commentary: performance of screening for congenital adrenal hyperplasia in infants born at term, it seems appropriate. Not so in preterm infants, where there is a high rate of false positives, which calls into question its inclusion within the neonatal screening. There are specific techniques but also more expensive, which could improve the effectiveness of screening. Should do more studies to rate this as well as economic studies that assess whether increase defficiency,offsets the increase in spending would the implementation of these screening techniques.

How to cite this article

Orejón de Luna G, Fernández Rodriguez M. ¿Es eficiente realizar cribado neonatal universal de hiperplasia suprarrenal congénita por déficit de 21-hidroxilasa? Evid Pediatr. 2012;8:40.

AVC | Critically appraised articles

Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y et al; DHCSF Study Group. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med. 2012;166:113-20.
Reviewers: Fernández Rodríguez M1, Orejón de Luna G2.
1Centro de Salud de Potes. Madrid. España.
2CS General Ricardos. Madrid. España.
Correspondence: Mercedes Fernández Rodríguez. Email: mer763@hotmail.com
Reception date: 29/04/2012
Acceptance date: 17/05/2012
Publication date: 23/05/2012

How to cite this article

Orejón de Luna G, Fernández Rodriguez M. ¿Es eficiente realizar cribado neonatal universal de hiperplasia suprarrenal congénita por déficit de 21-hidroxilasa? Evid Pediatr. 2012;8:40.

References

  1. Galbe Sánchez-Ventura J y Grupo PrevInfad/PAPPS Infancia y Adolescencia. Cribado Neonatal de metabolopatías. Rev Pediatr Aten Primaria. 2009;11:471-84.
  2. Rey Liste T, García Caerio AL. El cribado neonatal de la hiperplasia suprarrenal congénita: una revisión sistemática. Endocrinol Nutr. 2007;54:216-4.
  3. White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009;5:490-8.
  4. Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U et al. Newborn screening for congenital adrenal hyperplasia: additional steroide profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2007;92:2581-9.
  5. Grosse SD. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res. 2007;67:284-1.
  6. Galbe Sánchez-Ventura J. Cribado neonatal de metabolopatías congénitas. En: PrevInfand.

23/05/2012

Linked Comment